Alx Oncology Holdings (ALXO) Preferred Stock Liabilities (2019 - 2020)
Alx Oncology Holdings (ALXO) reported Preferred Stock Liabilities of $175.0 million for Q2 2020, up 148.77% on a YoY basis from $70.4 million in Q3 2019, and little changed sequentially from $175.0 million in Q1 2020.
Alx Oncology Holdings (ALXO) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Alx Oncology Holdings (ALXO) has 2 years of Preferred Stock Liabilities data on file, last reported at $175.0 million in Q2 2020.
- For the quarter ending Q2 2020, Preferred Stock Liabilities rose 148.77% year-over-year to $175.0 million; the trailing twelve-month figure through Jun 2020 stood at $175.0 million (up 148.77% YoY), and the FY2019 full-year result was $70.4 million, up 15.48% from the prior year.
- Preferred Stock Liabilities steadied at $175.0 million in Q2 2020, from $175.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $175.0 million in Q1 2020 to a low of $70.4 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 175.04 Mn |
| Mar 31, 2020 | 175.04 Mn |
| Dec 31, 2019 | 70.36 Mn |
| Sep 30, 2019 | 70.36 Mn |
| Jun 30, 2019 | 70.36 Mn |